EPISODE · Jan 29, 2026 · 48 MIN
Lung Cancer Research: 2025 Year in Review
from Conversations in Lung Cancer Research · host Thoracic Oncology Group Of Australasia (TOGA)
In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.00:00 Introduction to Lung Cancer Research Podcast00:37 Panel Introduction and Discussion Overview01:18 Lung Cancer Screening in Australia02:30 Impact of Screening on Diagnostic Services06:45 Screening Program Benefits and Challenges10:34 Future of Lung Cancer Screening15:54 Advancements in Diagnostic Technology20:57 Therapeutic Developments in Lung Cancer24:34 New Drug Listings and Their Impact40:04 Immunotherapy and Future Directions44:13 Conclusion and Final Thoughts Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
Embed this episode
What this episode covers
In this episode of 'Conversations in Lung Cancer Research,' hosted by A/Prof Mal Itchins, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Prof Nick Pavlakis from Royal North Shore Hospital and A/Prof Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the National Lung Cancer Screening Program (NLCSP), anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. This episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices. *This episode was recorded prior to the PBS update in December 2025.
NOW PLAYING
Lung Cancer Research: 2025 Year in Review
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.